Tofacitinib for Inflammatory Eye Disease

Status unconfirmed · Phase 2

Conditions studied: Uveitis, Scleritis

In brief

Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.

Key facts

Study ID

NCT03580343

Run by

Washington University School of Medicine

People needed

5

Starts

2019-04-04

Expected to finish

2021-04-04

Last updated by the study team

2021-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of uveitis
• a clinical response to steroids
• active disease requiring at least 10mg of prednisone daily (or steroid equivalent)

You may not qualify if…

• suspected or confirmed ocular infection
• chronic or recurring infections, such as HIV
• renal insufficiency that would preclude safe administration of tofacitinib

Where it is running

• Washington University in Saint Louis — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.